Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexza Pharmaceuticals, Inc.

http://www.alexza.com

Latest From Alexza Pharmaceuticals, Inc.

JPM 2024: ‘Economic Engine:’ Genomics News Abound From Exact, Guardant And Veracyte

The three genomics players all announced preliminary results prior to speaking, and all had more news to add about their recent success and their plans to grow the demand for cancer diagnostics.

Medical Device Diagnostics

Intas And mAbxience Strike Global Etanercept Deal

Intas and mAbxience have announced an exclusive licensing agreement covering mAbxience’s etanercept biosimilar candidate in more than 150 countries worldwide, including Europe and the US.

Deals Biosimilars

Turkey’s Abdi İbrahim Allies With mAbxience For ‘Unprecedented’ Technology Transfer

Five years after striking a biosimilars alliance with Iceland’s Alvotech, Turkish firm Abdi İbrahim – which boasts the country’s “largest biotech pharmaceutical manufacturing facility” – has shaken hands with Spanish developer mAbxience for technology transfer of an undisclosed oncology biosimilar.

Biosimilars Deals

Another Denosumab Deal For mAbxience In MEA

A further licensing deal for biosimilar denosumab has been struck by mAbxience, with MS Pharma set to register and market the Prolia/Xgeva rival in “select MEA markets.”

Deals Biosimilars
See All

Company Information

  • Other Names / Subsidiaries
    • Addicere Therapeutics, Inc.
UsernamePublicRestriction

Register